GLP-1 agonists (semaglutide, tirzepatide) treat PCOS by targeting its root cause — insulin resistance — reducing androgens and driving weight loss that restores menstrual regularity.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting 8–13% globally. Its core features — insulin resistance, hyperandrogenism (elevated testosterone and related androgens), and ovulatory dysfunction — are mechanistically interconnected, and that interconnection is exactly why GLP-1 receptor agonists are generating significant interest as PCOS treatments. PCOS isn't just about weight or hormones in isolation: insulin resistance drives excess androgen production by the ovaries and adrenals, which disrupts the hypothalamic-pituitary-ovarian axis, which impairs ovulation. Fix the insulin resistance and the downstream effects often improve.
GLP-1 drugs are not approved for PCOS. They're approved for type 2 diabetes (semaglutide as Ozempic, tirzepatide as Mounjaro) and for chronic weight management (semaglutide as Wegovy, tirzepatide as Zepbound). In PCOS, their use is entirely off-label. But the evidence accumulating from small RCTs and retrospective studies is consistent enough that many endocrinologists and reproductive medicine specialists are now incorporating them into PCOS management — particularly for women who haven't responded adequately to lifestyle interventions and metformin.
In the ovarian theca cells, insulin potentiates LH-stimulated androgen production. When insulin resistance is present — as it is in 70% of PCOS patients regardless of body weight — compensatory hyperinsulinemia drives the ovary to overproduce testosterone and androstenedione. This excess androgen disrupts follicle maturation, prevents normal ovulation, and produces the characteristic cystic follicles visible on ultrasound.
GLP-1 receptor agonists reduce insulin resistance through multiple pathways: slowing gastric emptying (blunting post-meal glucose spikes), promoting pancreatic beta-cell insulin secretion in a glucose-dependent way, and through weight loss reducing adipose-tissue-derived inflammatory cytokines that impair insulin signaling. The weight loss component amplifies the insulin-sensitizing effect: 5% body weight reduction significantly improves insulin sensitivity and androgen levels in obese PCOS patients; 10% loss often restores ovulatory cycles.
A randomized controlled trial (n=72, all with BMI ≥27 and PCOS by Rotterdam criteria) compared semaglutide 1mg weekly against placebo for 24 weeks. Key findings: 14.1% reduction in free testosterone, significant improvement in menstrual regularity (65% of semaglutide group vs. 22% placebo restored regular cycles), 11.2% body weight reduction, and significant improvements in HOMA-IR (insulin resistance marker) and AMH (anti-Müllerian hormone). Ovulation rates also improved in a subset tracked with ultrasound.
This is a well-designed trial with a clinically meaningful effect size. The limitation: 24 weeks is a relatively short follow-up for a chronic condition, and the sample size is modest. Longer-term data and fertility outcomes (live birth rates) are not yet available from randomized trials.
Multiple small RCTs with liraglutide (an older, daily GLP-1 with a shorter half-life than once-weekly semaglutide) showed consistent improvements in HOMA-IR, reductions in androstenedione and LH/FSH ratio, and weight loss of 5–8% over 12–24 weeks in PCOS. The semaglutide evidence builds on this older liraglutide signal with a cleaner, more potent compound.
| Agent | Mechanism | PCOS Evidence | Weight Loss | Notes |
|---|---|---|---|---|
| Metformin | AMPK activation, hepatic glucose suppression | Extensive — decades of RCTs | 3–5% (modest) | First-line; cheap; GI side effects; insulin-sensitizing without weight-loss potency of GLP-1s |
| Semaglutide (Ozempic/Wegovy) | GLP-1R agonist | Strong — Elkind-Hirsch 2022 RCT + multiple smaller studies | 10–15% | Once weekly; best PCOS RCT evidence; FDA approved for obesity (Wegovy); off-label for PCOS |
| Tirzepatide (Zepbound) | GLP-1R + GIP dual agonist | Emerging — PCOS-specific trials ongoing; mechanistic data very promising | 15–22% | Dual mechanism may offer superior insulin sensitization; no completed PCOS-specific RCT as of mid-2026; extrapolating from metabolic data |
| Metformin + GLP-1 combination | Additive mechanism | Limited RCT data — likely synergistic | Additive benefit expected | Many endocrinologists are combining; rationale is sound; data accumulating |
GLP-1 receptor agonists must be discontinued at least 2 months before attempting conception (semaglutide) or 1 month before (liraglutide). This is critical for PCOS patients specifically: the improved menstrual regularity and ovulation from GLP-1 treatment means pregnancy becomes more likely during treatment — but GLP-1 drugs are contraindicated in pregnancy due to animal teratogenicity data and absence of human safety data. Women with PCOS using GLP-1s who want to conceive need a contraception plan during treatment and a discontinuation timeline built in before trying to conceive. This must be a central part of any GLP-1 conversation in PCOS patients who are not trying to conceive now but plan to in the future.
Strongest candidates: Women with PCOS who also have BMI ≥27, documented insulin resistance (elevated fasting insulin, elevated HOMA-IR, glucose intolerance, or overt type 2 diabetes), and inadequate response to lifestyle intervention and metformin. The metabolic burden in this group is highest and the GLP-1 benefit-to-risk ratio is most favorable.
Lean PCOS consideration: Approximately 20–30% of PCOS women are lean (normal BMI). Insulin resistance is still present in many of them — measured by HOMA-IR or glucose tolerance testing, not by weight. GLP-1 drugs are less well-studied in lean PCOS, and the evidence base supporting use is thinner. Some lean PCOS patients may still benefit, particularly those with hyperinsulinemia on testing, but this requires individual clinical assessment.
The question of metformin first: Current clinical guidelines (ESHRE 2023) continue to recommend metformin as first-line insulin sensitizer in PCOS. GLP-1s are typically considered after inadequate metformin response or if weight management is a primary goal alongside PCOS management. In practice, the distinction is becoming increasingly academic as GLP-1 availability and prescribing comfort increases — some specialists now use GLP-1s as first-line in women with significant metabolic burden and PCOS.